TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Dec 31, 2025. Filed Feb 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 3, 2026
TEVA$42.97+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of changes in equity
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
| Teva shareholders’ equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Ordinary shares | |||||||||
| Number of shares (in millions) | Stated value | Additional paid-in capital | Retained earnings (accumulated deficit) | Accumulated other comprehensive income (loss) | Treasury shares | Total Teva share- holders’ equity | Non-controlling interests | Total equity | |
| (U.S. dollars in millions) | |||||||||
| Balance at January 1, 2023 | 1,217 | 57 | 27,688 | (12,975) | (2,838) | (4,128) | 7,804 | 794 | 8,598 |
| Changes during 2023: | |||||||||
| Net income (loss) | (559) | (559) | (56) | (615) | |||||
| Other comprehensive income (loss) | 141 | 141 | (50) | 91 | |||||
| Issuance of shares | 10 | * | * | * | * | ||||
| Stock-based compensation expense | 121 | 121 | 121 | ||||||
| Dividend to non-controlling interests** | (68) | (68) | |||||||
| Balance at December 31, 2023 | 1,227 | 57 | 27,807 | (13,534) | (2,697) | (4,128) | 7,506 | 620 | 8,126 |
| Changes during 2024: | |||||||||
| Net income (loss) | (1,639) | (1,639) | (320) | (1,959) | |||||
| Other comprehensive income (loss) | (447) | (447) | (61) | (508) | |||||
| Issuance of shares | 13 | 1 | * | 1 | 1 | ||||
| Stock-based compensation expense | 123 | 123 | 123 | ||||||
| Proceeds from exercise of options | 19 | 19 | 19 | ||||||
| Dividend to non-controlling interests** | (18) | (18) | |||||||
| Purchase of shares from non-controlling interests*** | (45) | (3) | (48) | (16) | (64) | ||||
| Reclassification to redeemable non-controlling interests**** | (142) | (142) | (198) | (340) | |||||
| Balance at December 31, 2024 | 1,240 | 58 | 27,764 | (15,173) | (3,148) | (4,128) | 5,373 | 7 | 5,380 |
| Changes during 2025: | |||||||||
| Net income (loss) | 1,410 | 1,410 | 1 | 1,411 | |||||
| Other comprehensive income (loss) | 757 | 757 | 757 | ||||||
| Issuance of shares | 16 | * | * | 1 | 1 | ||||
| Stock-based compensation expense | 157 | 157 | 157 | ||||||
| Proceeds from exercise of options | 47 | 47 | 47 | ||||||
| Purchase of shares from redeemable non-controlling interests**** | 165 | 165 | 165 | ||||||
| Dividend to non-controlling interests***** | (4) | (4) | |||||||
| Balance at December 31, 2025 | 1,256 | $58 | $28,133 | $(13,762) | $(2,391) | $(4,128) | $7,910 | $4 | $7,914 |
| * | Represents an amount less than $0.5 million. |
|---|
| ** | Mainly in connection with a declaration of dividends to non-controlling interests in Teva’s business venture in Japan. |
|---|
| *** | Purchase of shares from non-controlling interests in a Teva’s subsidiary in Switzerland. |
|---|
| **** | In connection with the sale of Teva’s business venture in Japan. See note 22. |
|---|
| ***** | In connection with a declaration of dividends to non-controlling interests in Teva’s subsidiary in Bulgaria. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.